Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Early Phase 1
1(33.3%)
3Total
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06439056Phase 1Completed

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

Role: lead

NCT05643248Early Phase 1Completed

To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects

Role: lead

NCT05048498Phase 1Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Role: lead

All 3 trials loaded